BioNTech wants “to help eradicate malaria” by using the same breakthrough mRNA technology it used to develop its coronavirus vaccine, the pharmaceutical company said on Monday. The Germany-based group said it aimed to begin clinical malaria vaccine trials by the end of 2022. If successful, the shot could be a major development in the fight against malaria, which kills more than 400,000 people a year — mainly young children in Africa. The disease is caused by a parasite that commonly infects a certain type of mosquito which feeds on humans. “We will do whatever it takes to develop a safe and effective mRNA-based malaria vaccine that will prevent the disease, reduce mortality and ensure a sustainable solution for the African continent and other regions affected by this disease,” BioNTech CEO Ugur Sahin said in a statement. Scientists believe mRNA technology, which prompts an immune response by delivering genetic molecules containing the code for key parts of a pathogen into human cells, could be a game-changer against several diseases. Using this technology is also a faster way of developing a vaccine than traditional methods and could bring an end to the decades-long search for a reliable malaria shot.
SOURCE: DEUTSCHE WELLE
More Stories
Namibia Identified as a Strategic Enabler of the European Union’s Decarbonization Agenda
Meet Burkina Faso’s New Leader
Is Kipchoge Well On the Way to Breaking the Elusive Sub-2-hour Marathon Barrier?
No Room for Ex Burkina Leader
Africa’s Youth Set the Tone for Cop27
A Rundown on 5G’s Status among Africa’s First Movers
Nigeria Will Award Contracts for its Flared Gas by the End of December
Residents of Hwange Live in Fear as Mining Firm Fails to Stop Raging Underground Blazes
Climate Change and the Green Morocco Programme Threatens the Livelihood of Nomads
SA is Headed for a Showdown with Tobacco Companies
Robin Roberts Explores Culture, History And Fashion in Ghana with ‘Black Panther’ Star
Ivory Coast’s Obou Gbais is Painting the Story of His Life